PMC4563802_01
LDL-C response to lomitapide over time. LDL-C values from the time of patient enrollment in the phase 3 study are reported. Arrows indicate key events over the course of treatment. Numbers indicate lomitapide doses. *Prior to this lipid measurement, rosuvastatin and ezetimibe were not taken for 38 days, and lomitapide was not taken for 5 days for non-study-related reasons.
nihms719097f1.jpg
PMC4563802_01_nihms719097f1.jpg
F1
The cumulative LDL-C response, along with comments on dose and liver function tests (LFT) changes are charted in Figure 1 and Figure 2.
Transaminase levels and percent hepatic fat content over time. Alanine aminotransferase and aspartate aminotransferase (ALT and AST) and percent hepatic fat content, measured by nuclear magnetic resonance spectroscopy, from the time of patient enrollment in the phase 3 study are reported.
nihms719097f2.jpg
PMC4563802_01_nihms719097f2.jpg
F2
The cumulative LDL-C response, along with comments on dose and liver function tests (LFT) changes are charted in Figure 1 and Figure 2. She experienced some expected non-serious adverse events of nausea, and some mild, transient LFT elevations, with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) not reaching greater than 2.3 times the upper limit of normal (xULN.) (Figure 2). The patient's hepatic fat content was 0.86% at baseline and peaked at 11.85% at week 26 (Figure 2).